Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: Data from two multicentre randomised trials

Vaccine

Volumn 30, Issue 45, 2012, Pages 6483-6491

  Peeters, Mathieu ^a   Regnerb, Stefan ^b   Vaman, Tejaswini ^c   Devaster, Jeanne Marie ^a   Rombo, Lars ^d  

^a GSK   (Belgium)

^b Gemeinschaftspraxis Mainz Mitte am Gesundheitscentrum   (Germany)

^c InVentiv Health ^*  (India)

^d Sormland County Council   (Sweden)

Author keywords

AS03 adjuvanted A(H1N1)pmd09 vaccine; Co administration; Elderly; Influenza vaccine; Pandemic; Sequential

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; PLACEBO;

ADULT; AGED; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GERMANY; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SWEATING; SWEDEN; SYMPTOM; TREATMENT REFUSAL;

ADJUVANTS, IMMUNOLOGIC; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; SWEDEN; VACCINATION; VACCINES, INACTIVATED;

EID: 84866517659     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.081     Document Type: Article

References (32)

1. General Directorate of Epidemiology MoHM, Pan American Health Organization, World Health Organization, Public Health Agency of Canada, Influenza Div NCfIaRDC. Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 2009;58(17):467-70.
2. General Directorate of Epidemiology MoHM, Pan American Health Organization, World Health Organization, Public Health Agency of Canada, CDC (United States). Update: novel influenza A (H1N1) virus infections - worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep 2009;58(17):453-8.
3. Ginsberg M., Hopkins J., Maroufi A., Dunne G., Sunega D.R., Giessick J., et al. Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 2009, 58(15):400-402.
4. Garten R.J., Davis C.T., Russell C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325(5937):197-201.
5. Fraser C., Donnelly C.A., Cauchemez S., Hanage W.P., Van Kerkhove M.D., Hollingsworth T.D., et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009, 324(5934):1557-1561.
6. Greenbaum J.A., Kotturi M.F., Kim Y., Oseroff C., Vaughan K., Salimi N., et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A 2009, 106(48):20365-20370.
7. McCullers J.A., Van De Velde L.A., Allison K.J., Branum K.C., Webby R.J., Flynn P.M. Recipients of vaccine against the 1976 swine flu have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis 2010, 50(11):1487-1492.
8. Skountzou I., Koutsonanos D.G., Kim J.H., Powers R., Satyabhama L., Masseoud F., et al. Immunity to pre-1950 H1N1 influenza viruses confers cross-protection against the pandemic swine-origin 2009 A (H1N1) influenza virus. J Immunol 2010, 185(3):1642-1649.
9. Nicoll A. A new decade, a new seasonal influenza: the Council of the European Union Recommendation on seasonal influenza vaccination. Euro Surveill 2010, 15(1). pii=19458. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19458.
10. Donaldson L.J., Rutter P.D., Ellis B.M., Greaves F.E.C., Mytton O.T., Pebody R.G., et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 2009, 339:b5213.
11. Curran M.P., Leroux-Roels I. Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly. Drugs 2010, 70(12):1519-1543.
12. Roman F., Vaman T., Gerlach B., Markendorf A., Gillard P., Devaster J.M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010, 28(7):1740-1745.
13. Roman F., Vaman T., Kafeja F., Hanon E., Van D.P. AS03(A)-adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis 2010, 51(6):668-677.
14. A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 2010, 28:849-857.
15. Committee for Medicinal Products for Human Use. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. London: The European Agency for the Evaluation of Medicines for Human Use. [Publication no. CHMP/VWP/263499/2006]. Available from: 2007 [accessed: 02.03.12]. http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003872.pdf.
16. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines. London: The European Agency for the Evaluation of Medicinal Products. [Publication no. CPMP/BWP/214/96]. Available from: 1997 [accessed: 02.03.12]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
17. Hehme N.W., Künzel W., Petschke F., Türk G., Raderecht C., van Hoecke C., et al. Ten years of experience with the trivalent split-influenza vaccine, Fluarix(TM). Clin Drug Invest 2002, 22(11):751-769.
18. Hehme N., Engelmann H., Kuenzel W., Neumeier E., Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004, 103:163-171.
19. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37(4):937-943.
20. Heijmans S., De Meulemeester M., Reynders P., Giet D., Demanet E., Devresse P.Y., et al. Immunogenicity profile of a 3.75μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial. J Infect Dis 2011, 203(8):1054-1062.
21. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361(25):2405-2413.
22. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361(25):2424-2435.
23. Carmona A., Omenaca F., Tejedor J.C., Merino J.M., Vaman T., Dieussaert I., et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. Vaccine 2010, 28(36):5837-5844.
24. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375(9708):41-48.
25. Roman F., Clement F., Dewe W., Walravens K., Maes C., Willekens J., et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011, 18(5):835-843.
26. Choi Y.S., Baek Y.H., Kang W., Nam S.J., Lee J., You S., et al. Reduced antibody responses to the pandemic (H1N1) 2009 vaccine after recent seasonal influenza vaccination. Clin Vaccine Immunol 2011, 18(9):1519-1523.
27. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303(1):37-46.
28. Huijskens E., Rossen J., Mulder P., van Beek R., van Vugt H., Verbakel J., et al. Immunogenicity, boostability, and sustainability of the immune response after vaccination against influenza A virus (H1N1) 2009 in a healthy population. Clin Vaccine Immunol 2011, 18(9):1401-1405.
29. Centers for Disease Control and Prevention (CDC) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011 2011, 60(33):1128-1132.
30. Fiore A.E., Uyeki T.M., Broder K., Finelli L., Euler G.L., Singleton J.A., et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010 2010, 59(RR-8):1-62.
31. Wichmann O., Stocker P., Poggensee G., Altmann D., Walter D., Hellebrand W., et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010. Euro Surveill 2010, 15(18).
32. Yin J.K., Chow M.Y., Khandaker G., King C., Richmond P., Heron L., et al. Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses. Vaccine 2012, 30(21):3209-3222.